SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-12-032960
Filing Date
2012-05-04
Accepted
2012-05-04 10:19:40
Documents
10
Period of Report
2012-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q a12-8730_110q.htm 10-Q 737411
2 EX-31.1 a12-8730_1ex31d1.htm EX-31.1 12589
3 EX-31.2 a12-8730_1ex31d2.htm EX-31.2 13204
4 EX-32.1 a12-8730_1ex32d1.htm EX-32.1 8336
  Complete submission text file 0001104659-12-032960.txt   2988914

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20120331.xml EX-101.INS 363994
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldx-20120331.xsd EX-101.SCH 15221
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cldx-20120331_cal.xml EX-101.CAL 40046
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cldx-20120331_lab.xml EX-101.LAB 263439
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldx-20120331_pre.xml EX-101.PRE 127889
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldx-20120331_def.xml EX-101.DEF 79715
Mailing Address 119 FOURTH AVE NEEDHAM MA 02494-2725
Business Address 119 FOURTH AVE NEEDHAM MA 02494 7814330771
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 12812311
SIC: 2835 In Vitro & In Vivo Diagnostic Substances